Clinical Trial: Efficacy and Safety of TACE Combined with Tislelizumab or TACE Alone After Curative Resection of Hepatocellular Carcinoma With Microvascular Invasion (MVI): A Prospective Cohort Study (China)

Posted On: 2026-11-03

China, Nov. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of TACE Combined with Tislelizumab or TACE Alone After Curative Resection of Hepatocellular Carcinoma With Microvascular Invasion (MVI): A Prospective Cohort Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135819

Registration Time: 2026/11/02

Type: Observational study

Primary Sponsor: Beijing Youan Hospital, Capital Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=349304

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy and Safety of TACE Combined with Tislelizumab or TACE Alone After Curative Resection of Hepatocellular Carcinoma With Microvascular Invasion (MVI): A Prospective Cohort Study (China)